Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Multi-dose Administration in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2015
Price :
$35
*
At a glance
- Drugs Blisibimod (Primary) ; Blisibimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Amgen
- 13 Apr 2015 New trial record